In short
PF-07328948 is an investigational medicine being studied in adults with heart failure. One Phase 2 trial is currently authorised, planning to enrol 620 participants. The trial compares PF-07328948 with placebo over 36 weeks, measuring clinical events, physical function and symptoms.
PF-07328948 is an investigational substance being studied in adults with heart failure. The only registered trial is a Phase 2 study called BRANCH-HF, which is authorised and plans to enrol 620 participants.
Key points
- PF-07328948 is an investigational substance with no marketing authorisation in these records.
- The only registered trial is a Phase 2 study in adults with heart failure.
- The trial is authorised and plans to enrol 620 participants.
- Participants receive PF-07328948 or placebo orally every day for 36 weeks.
- The study measures cardiovascular death, worsening heart failure events, six-minute walk distance and quality of life.
What is PF-07328948?
PF-07328948 is an investigational medicine. No marketing authorisation is recorded in the registry data, meaning it has not yet been approved as a medicine. It is given as a tablet by mouth. The trial record lists it only under its development code, PF-07328948.
How does PF-07328948 work?
The registry record does not describe the mechanism of action of PF-07328948. The trial is designed to compare its effect with placebo on clinical events, physical function and symptoms in people with heart failure.
Which conditions is PF-07328948 studied for?
- Heart failure — specifically heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF), a form of heart failure in which the heart pumps blood but does not relax or fill properly.
How is PF-07328948 given?
In the registered trial, PF-07328948 is given as a tablet taken by mouth. The trial also uses a matching placebo tablet. The exact milligram dose is not reported in the registry record.
What does the clinical trial show?
One Phase 2 trial, BRANCH-HF, is authorised but does not yet report results. It is an interventional study comparing PF-07328948 with placebo, both given daily for 36 weeks, in 620 adults with heart failure with mildly reduced or preserved ejection fraction.
The main measure is a hierarchical combination of several outcomes assessed together. It includes adjudicated clinical events through week 36: cardiovascular death, worsening heart failure events resulting in hospitalisation, worsening heart failure events resulting in intravenous diuretic during an urgent heart failure visit, and worsening heart failure events resulting in oral diuretic intensification in an outpatient setting. It also includes the change from baseline in six-minute walk distance at week 36 and the change from baseline in the Kansas City Cardiomyopathy Questionnaire total symptom score at week 36.
Participants are adults with heart failure with mildly reduced or preserved ejection fraction. The study does not report results yet, so no conclusions about benefit can be drawn.
What side effects are known?
The registry record does not report side effects for PF-07328948. No supplementary sources were provided.